S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Here's Bill Bonner's "4th and Final Prediction" (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Here's Bill Bonner's "4th and Final Prediction" (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Here's Bill Bonner's "4th and Final Prediction" (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Here's Bill Bonner's "4th and Final Prediction" (Ad)
NASDAQ:ICPT

Intercept Pharmaceuticals - ICPT Stock Forecast, Price & News

$17.60
+1.53 (+9.52%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$16.34
$18.19
50-Day Range
$11.23
$17.60
52-Week Range
$10.81
$20.50
Volume
1.69 million shs
Average Volume
849,542 shs
Market Capitalization
$524.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.36

Intercept Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
21.4% Upside
$21.36 Price Target
Short Interest
Bearish
45.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.13
Upright™ Environmental Score
News Sentiment
0.27mentions of Intercept Pharmaceuticals in the last 14 days
Based on 23 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.92) to ($3.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

1032nd out of 1,135 stocks

Pharmaceutical Preparations Industry

507th out of 557 stocks

ICPT stock logo

About Intercept Pharmaceuticals (NASDAQ:ICPT) Stock

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Intercept Pharmaceuticals Stock Up 9.5 %

Shares of NASDAQ:ICPT traded up $1.53 during trading on Friday, reaching $17.60. 1,685,401 shares of the company traded hands, compared to its average volume of 849,542. The firm has a fifty day simple moving average of $14.08 and a 200 day simple moving average of $15.56. The firm has a market cap of $524.48 million, a P/E ratio of -8.11 and a beta of 1.24. Intercept Pharmaceuticals has a 1-year low of $10.81 and a 1-year high of $20.50.

Intercept Pharmaceuticals (NASDAQ:ICPT - Get Rating) last issued its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.15). The business had revenue of $100.40 million for the quarter, compared to the consensus estimate of $94.85 million. As a group, research analysts anticipate that Intercept Pharmaceuticals will post -2.92 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Cowen lowered their price objective on shares of Intercept Pharmaceuticals to $22.00 in a research note on Tuesday. Raymond James lifted their price target on shares of Intercept Pharmaceuticals from $23.00 to $26.00 and gave the stock an "outperform" rating in a research report on Thursday, August 4th. SVB Leerink decreased their price target on shares of Intercept Pharmaceuticals from $27.00 to $21.00 and set a "market perform" rating on the stock in a research report on Friday, July 8th. StockNews.com lowered shares of Intercept Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, August 4th. Finally, HC Wainwright decreased their price objective on shares of Intercept Pharmaceuticals from $18.00 to $16.00 and set a "neutral" rating for the company in a research note on Monday, August 8th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $21.36.

Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Stock News Headlines

Intercept Pharmaceuticals (NASDAQ:ICPT) PT Lowered to $16.00
Where Intercept Pharmaceuticals Stands With Analysts
Intercept Pharmaceuticals Inc Stock News
See More Headlines
Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Company Calendar

Last Earnings
8/03/2022
Today
8/13/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ICPT
CUSIP
45845P10
Employees
437
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.36
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+21.4%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
10 Analysts

Profitability

Net Income
$-91,430,000.00
Pretax Margin
-18.31%

Debt

Sales & Book Value

Annual Sales
$363.47 million
Book Value
($12.41) per share

Miscellaneous

Free Float
22,736,000
Market Cap
$524.48 million
Optionable
Optionable
Beta
1.24

Key Executives

  • Mr. Jerome B. Durso (Age 54)
    Pres, CEO & Director
    Comp: $1.16M
  • Mr. Andrew Saik (Age 53)
    Chief Financial Officer
    Comp: $485.07k
  • Mr. Rocco Venezia (Age 46)
    Chief Accounting Officer & Treasurer
    Comp: $660.62k
  • Mr. Jared M. Freedberg J.D. (Age 54)
    Gen. Counsel
    Comp: $691.46k
  • Dr. M. Michelle Berrey M.D. (Age 55)
    M.P.H., MPH., Pres of R&D and Chief Medical Officer
    Comp: $732.13k
  • Mr. Bryan Ball (Age 52)
    Chief Quality Officer & Sr. VP of Operations
  • Mr. David Ford (Age 52)
    Chief HR Officer
  • Dr. Mark Pruzanski M.D. (Age 54)
    Founder, Advisor & Director
  • Ms. Linda M. Richardson (Age 58)
    Exec. VP & Chief Commercial Officer
  • Paul Nitschmann
    Sr. VP of Regulatory Affairs













ICPT Stock - Frequently Asked Questions

Should I buy or sell Intercept Pharmaceuticals stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ICPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares.
View ICPT analyst ratings
or view top-rated stocks.

What is Intercept Pharmaceuticals' stock price forecast for 2022?

10 brokerages have issued 1 year target prices for Intercept Pharmaceuticals' stock. Their ICPT share price forecasts range from $10.00 to $32.00. On average, they anticipate the company's share price to reach $21.36 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price.
View analysts price targets for ICPT
or view top-rated stocks among Wall Street analysts.

How have ICPT shares performed in 2022?

Intercept Pharmaceuticals' stock was trading at $16.29 at the beginning of 2022. Since then, ICPT stock has increased by 8.0% and is now trading at $17.60.
View the best growth stocks for 2022 here
.

When is Intercept Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our ICPT earnings forecast
.

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its earnings results on Wednesday, August, 3rd. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.15. The biopharmaceutical company earned $100.40 million during the quarter, compared to the consensus estimate of $94.85 million.

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?

32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include EULAV Asset Management (1.33%), Renaissance Technologies LLC (1.32%), Northern Trust Corp (0.83%), Pictet Asset Management SA (0.53%), Rafferty Asset Management LLC (0.51%) and SG Americas Securities LLC (0.38%). Insiders that own company stock include Christian Weyer, David A Ford, Gail Cawkwell, Jason Campagna, Lisa Bright, Mark Pruzanski, Paolo Fundaro, Ryan T Sullivan, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju.
View institutional ownership trends
.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $17.60.

How much money does Intercept Pharmaceuticals make?

Intercept Pharmaceuticals (NASDAQ:ICPT) has a market capitalization of $524.48 million and generates $363.47 million in revenue each year. The biopharmaceutical company earns $-91,430,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.

How many employees does Intercept Pharmaceuticals have?

The company employs 437 workers across the globe.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The official website for the company is www.interceptpharma.com. The biopharmaceutical company can be reached via phone at (646) 747-1000, via email at investors@interceptpharma.com, or via fax at 646-747-1001.

This page (NASDAQ:ICPT) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.